Drug
Nifurtimox
Nifurtimox is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Phase Distribution
Ph phase_1
1
17%
Ph phase_2
4
67%
Ph phase_3
1
17%
Phase Distribution
1
Early Stage
4
Mid Stage
1
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
1(16.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(5)
Other(1)
Detailed Status
Completed5
unknown1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (16.7%)
Phase 24 (66.7%)
Phase 31 (16.7%)
Trials by Status
completed583%
unknown117%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_2
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
NCT00601003
completedphase_2
New Therapies and Biomarkers for Chagas Infection
NCT03981523
completedphase_2
Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
NCT01685827
unknownphase_2
CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)
NCT02369978
completedphase_3
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
NCT00146627
Clinical Trials (6)
Showing 6 of 6 trials
NCT00601003Phase 2
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
NCT03981523Phase 2
New Therapies and Biomarkers for Chagas Infection
NCT01685827Phase 2
Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
NCT02369978Phase 2
CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)
NCT00146627Phase 3
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
NCT00486564Phase 1
Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6